Innovative Gene Therapy Approach To Prevent Amputations In Patients Suffering Severe Peripheral Artery Disease

Innovative Gene Therapy Approach To Prevent Amputations In Patients Suffering Severe Peripheral Artery Disease
Cardiologists at Rush University Medical Center are studying an investigational medication to prevent amputations in patients suffering the most severe form of peripheral arterial disease. The study involves use of a highly innovative gene therapy approach to promote new blood vessel growth in the legs of patients with critical limb ischemia.

Expanding Festive Waistlines Put Thousands At Risk Of Type 2 Diabetes
Over-indulgence in too many calorific treats such as mince pies (around 200 calories each), Christmas cake (approximately 250 calories per slice) and mulled wine (about 250 calories in a glass) can leave us all struggling to buckle our belts in the New Year. Having a large waist means you are up to eleven times more likely to develop Type 2 diabetes and being overweight or obese is one of the strongest risk factors for developing Type 2 diabetes.

Andromeda Biotech Announces Successful Phase III Interim Results Of Its Lead Product, DiaPep277 For Type 1 Diabetes
Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (CBI), focused on the development of innovative treatment for autoimmune diabetes announces positive results following the Phase III interim analysis for the company's lead product, DiaPep277 for the treatment of Type 1 diabetes.

100,000 People With Diabetes Call '999' A Year
People with diabetes made more than 100,000 emergency calls in the UK last year, according to Diabetes UK. The charity warns that although the ambulance service has recently experienced an unprecedented volume of calls with many for non-emergency situations, most calls from people with diabetes are for severe hypoglycaemia (hypo).

SciClone Announces First Patient Enrolled In Phase 2 Clinical Trial Using SCV-07 To Prevent Oral Mucositis

SciClone Announces First Patient Enrolled In Phase 2 Clinical Trial Using SCV-07 To Prevent Oral Mucositis
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of its first patient in its phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of SCV-07 for prevention of oral mucositis (OM) in patients receiving radio-chemotherapy for the treatment of head and neck cancer.